Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Closes Tm Bioscience Acquisition

NEW YORK (GenomeWeb News) — Luminex today said it has closed its acquisition of Tm Bioscience after receiving the green light from a Canadian court on Wednesday.
 
Under the terms of the deal, disclosed last December, Luminex will acquire all of the outstanding shares of Tm. Tm shareholders will receive .6 shares of Luminex common stock for each Tm share, leaving Tm holders with roughly 9 percent of Luminex’s stock.
 
Luminex CEO and President Patrick Balthrop said the company plans to market Tm’s molecular detection chemistries, assay kits, and reagents through its distribution partners.
The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.